Keiran S. M. Smalley Department of Tumor Biology University of South Florida, H. Lee Moffitt Cancer Center & Research Institute Biography Publications Institution JoVE Articles Keiran S. M. Smalley has not added a biography. If you are Keiran S. M. Smalley and would like to personalize this page please email our Author Liaison for assistance. Publications Differential Requirements for CD4+ T Cells in the Efficacy of the Anti-PD-1+LAG-3 and Anti-PD-1+CTLA-4 Combinations in Melanoma Flank and Brain Metastasis Models Journal for Immunotherapy of Cancer. Dec, 2023 | Pubmed ID: 38056899 HDAC8-mediated Inhibition of EP300 Drives a Transcriptional State That Increases Melanoma Brain Metastasis Nature Communications. Nov, 2023 | Pubmed ID: 38030596 Acral Melanoma: New Insights into the Immune and Genomic Landscape Neoplasia (New York, N.Y.). Dec, 2023 | Pubmed ID: 37913653 HDAC11 Activity Contributes to MEK Inhibitor Escape in Uveal Melanoma Cancer Gene Therapy. Dec, 2022 | Pubmed ID: 35332245 Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma The Journal of Investigative Dermatology. Jan, 2022 | Pubmed ID: 34565560 Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2021 | Pubmed ID: 34035069 Targeted Therapy Given After Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models Through Sustained Antitumor Immunity Cancer Immunology Research. May, 2021 | Pubmed ID: 33653716 MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Dec, 2020 | Pubmed ID: 33355300 Two Worlds Collide: Unraveling the Role of the Immune System in BRAF-MEK Inhibitor Responses Cancer Discovery. 02, 2020 | Pubmed ID: 32024680 Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 05, 2020 | Pubmed ID: 31924735 Translational Pathology, Genomics and the Development of Systemic Therapies for Acral Melanoma Seminars in Cancer Biology. 04, 2020 | Pubmed ID: 31689494 Leveraging Transcriptional Dynamics to Improve BRAF Inhibitor Responses in Melanoma EBioMedicine. Oct, 2019 | Pubmed ID: 31594749 HDAC Inhibition Enhances the Efficacy of MEK Inhibitor Therapy in Uveal Melanoma Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 09, 2019 | Pubmed ID: 31227503 Pharmacological Research and Cancer: A Call to Arms Pharmacological Research. 08, 2019 | Pubmed ID: 31158465 HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy Cancer Research. 06, 2019 | Pubmed ID: 30987999 Combined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant Melanoma Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 11, 2018 | Pubmed ID: 29674508 ERK Inhibition: A New Front in the War Against MAPK Pathway-Driven Cancers? Cancer Discovery. 02, 2018 | Pubmed ID: 29431672 The Biology and Therapeutic Management of Melanoma Brain Metastases Biochemical Pharmacology. 07, 2018 | Pubmed ID: 29278675 Get with the Program! Stemness and Reprogramming in Melanoma Metastasis The Journal of Investigative Dermatology. 01, 2018 | Pubmed ID: 29273143 The Blood Brain Barrier and BRAF Inhibitors: Implications for Patients with Melanoma Brain Metastases Pharmacological Research. 09, 2018 | Pubmed ID: 29146209 Ceritinib Enhances the Efficacy of Trametinib in -Wild-Type Melanoma Cell Lines Molecular Cancer Therapeutics. 01, 2018 | Pubmed ID: 29133622 Increased Immunity and BRAF Inhibition: Yet Another Argument for Combination Therapy? Pharmacological Research. Nov, 2016 | Pubmed ID: 27392741 The Role of Phenotypic Plasticity in the Escape of Cancer Cells from Targeted Therapy Biochemical Pharmacology. Dec, 2016 | Pubmed ID: 27349985 Combination Therapies for Melanoma: A New Standard of Care? American Journal of Clinical Dermatology. Apr, 2016 | Pubmed ID: 26860106 Pharmacological Research and Precision Cancer Medicine: A Call for Manuscripts Pharmacological Research. Dec, 2015 | Pubmed ID: 26542638 BRAF Inhibition Generates a Host-Tumor Niche That Mediates Therapeutic Escape The Journal of Investigative Dermatology. Dec, 2015 | Pubmed ID: 26302068 XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation The Journal of Investigative Dermatology. Oct, 2015 | Pubmed ID: 26039542 Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research Vincent Law1,2, Inna Smalley3, Brittany R. Evernden2, Margaret Baldwin4, Keiran S. M. Smalley1, Peter A. Forsyth1,2 1Department of Tumor Biology, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, 2Department of Neuro-Oncology, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, 3Department of Cancer Physiology, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, 4Department of Comparative Medicine, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute JoVE 66071 Cancer Research A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease Vincent Law1,2, Margi Baldwin3, Ganesan Ramamoorthi4, Krithika Kodumudi4, Nam Tran1, Inna Smalley5, Derek Duckett6, Pawel Kalinski7, Brian Czerniecki4, Keiran S. M. Smalley2, Peter A. Forsyth1,2 1Department of Neuro-Oncology, H. Lee Moffitt Cancer Center & Research Institute, 2Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, 3Department of Comparative Medicine, University of South Florida, 4Department of Breast Oncology, H. Lee Moffitt Cancer Center & Research Institute, 5Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, 6Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, 7Department of Medical Oncology, Roswell Park Comprehensive Cancer Center JoVE 62033 Cancer Research
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research Vincent Law1,2, Inna Smalley3, Brittany R. Evernden2, Margaret Baldwin4, Keiran S. M. Smalley1, Peter A. Forsyth1,2 1Department of Tumor Biology, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, 2Department of Neuro-Oncology, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, 3Department of Cancer Physiology, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, 4Department of Comparative Medicine, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute JoVE 66071 Cancer Research
A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease Vincent Law1,2, Margi Baldwin3, Ganesan Ramamoorthi4, Krithika Kodumudi4, Nam Tran1, Inna Smalley5, Derek Duckett6, Pawel Kalinski7, Brian Czerniecki4, Keiran S. M. Smalley2, Peter A. Forsyth1,2 1Department of Neuro-Oncology, H. Lee Moffitt Cancer Center & Research Institute, 2Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, 3Department of Comparative Medicine, University of South Florida, 4Department of Breast Oncology, H. Lee Moffitt Cancer Center & Research Institute, 5Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, 6Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, 7Department of Medical Oncology, Roswell Park Comprehensive Cancer Center JoVE 62033 Cancer Research